Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)
Business Wire India The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE (ALS trial with Daily ORal Edaravone), with FNP122 in amyotrophic lateral…